作者
Matthew R Moore, Ruth Link-Gelles, William Schaffner, Ruth Lynfield, Catherine Lexau, Nancy M Bennett, Susan Petit, Shelley M Zansky, Lee H Harrison, Arthur Reingold, Lisa Miller, Karen Scherzinger, Ann Thomas, Monica M Farley, Elizabeth R Zell, Thomas H Taylor, Tracy Pondo, Loren Rodgers, Lesley McGee, Bernard Beall, James H Jorgensen, Cynthia G Whitney
发表日期
2015/3/1
期刊
The Lancet Infectious Diseases
卷号
15
期号
3
页码范围
301-309
出版商
Elsevier
简介
Background
In 2000, seven-valent pneumococcal conjugate vaccine (PCV7) was introduced in the USA and resulted in dramatic reductions in invasive pneumococcal disease (IPD) and moderate increases in non-PCV7 type IPD. In 2010, PCV13 replaced PCV7 in the US immunisation schedule. We aimed to assess the effect of use of PCV13 in children on IPD in children and adults in the USA.
Methods
We used laboratory-based and population-based data on incidence of IPD from the Active Bacterial Core surveillance (part of the Centers for Disease Control and Prevention's Emerging Infections Program) in a time-series model to compare rates of IPD before and after the introduction of PCV13. Cases of IPD between July 1, 2004, and June 30, 2013, were classified as being caused by the PCV13 serotypes against which PCV7 has no effect (PCV13 minus PCV7). In a time-series model, we used an expected …
学术搜索中的文章
MR Moore, R Link-Gelles, W Schaffner, R Lynfield… - The Lancet Infectious Diseases, 2015